Akkermansia Muciniphila Supplementation for Improved Immunotherapy Efficacy in NSCLC or RCC Patients

This study focuses on a bacterium called Akkermansia muciniphila, which naturally exists in the healthy human gut. Research shows that the presence of this bacterium in patients with Non-Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) is linked with the effectiveness of immunotherapy. The study aims to explore if giving a specific strain of this bacterium, Oncobax®-AK, to cancer patients undergoing immunotherapy can improve the treatment's efficacy, particularly for those with NSCLC or RCC who lack sufficient amounts of Akkermansia in their gut. Participants in this study will orally take Oncobax®-AK. The study's primary goal is to measure the Objective Response Rate, which indicates how well the treatment shrinks the tumor. This will be evaluated using a specific set of criteria called iRECIST. The study hopes to determine if Oncobax®-AK can enhance the response to immunotherapy in patients with NSCLC or RCC.